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ABSTRACT
Objective:  We aimed to evaluate the prognostic and predictive value of the nucleotide 
excision repair-related gene GTF2H5, which is localized at the 6q24.2-26 deletion previously 
reported by our group to predict longer survival of high-grade serous ovarian cancer patients.
Methods:  In order to test if protein levels of GTF2H5 are associated with patients' outcome, 
we performed GTF2H5 immunohistochemical staining in 139 high-grade serous ovarian 
carcinomas included in tissue microarrays. Upon stratification of cases into high- and low-
GTF2H5 staining categories (> and ≤ median staining, respectively) Kaplan-Meier and log-
rank test were used to estimate patients’ survival and assess statistical differences. We also 
evaluated the association of GTF2H5 with survival at the transcriptional level by using the 
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on-line Kaplan-Meier plotter tool, which includes gene expression and survival data of 855 
high-grade serous ovarian cancer patients from 13 different datasets. Finally, we determined 
whether stable short hairpin RNA-mediated GTF2H5 downregulation modulates cisplatin 
sensitivity in the SKOV3 and COV504 cell lines by using cytotoxicity assays.
Results:  Low expression of GTF2H5 was associated with longer 5-year survival of patients 
at the protein (hazard ratio [HR], 0.52; 95% CI, 0.29 to 0.93; p=0.024) and transcriptional 
level (HR, 0.80; 95% CI, 0.65 to 0.97; p=0.023) in high-grade serous ovarian cancer patients. 
We confirmed the association with 5-year overall survival (HR, 0.55; 95% CI, 0.38 to 0.78; 
p=0.0007) and also found an association with progression-free survival (HR, 0.72; 95% CI, 
0.54 to 0.96; p=0.026) in a homogenous group of 388 high-stage (stages III-IV using the 
International Federation of Gynecology and Obstetrics staging system), optimally debulked 
high-grade serous ovarian cancer patients. GTF2H5-silencing induced a decrease of the half 
maximal inhibitory concentration upon cisplatin treatment in GTF2H5-silenced ovarian 
cancer cells.
Conclusion:  Low levels of GTF2H5 are associated with enhanced prognosis in high-grade 
serous ovarian cancer patients and may contribute to cisplatin sensitization.
Keywords: Cisplatin-Sensitivity; DNA Repair; GTF2H5; Ovarian Epithelial Cancer; Survival; 
6q24-26 Deletion
INTRODUCTION
Epithelial ovarian cancer (EOC) is the most deadly of gynecological malignancies and the fifth 
most frequent cause of cancer death in women in developed countries [1]. High-grade serous 
ovarian carcinoma (HGSOC) is the most common and aggressive EOC histotype and accounts 
for the majority (60% to 80%) of EOC deaths [2]. Although in the last decades treatment has 
advanced significantly thanks to improved surgical techniques and chemotherapy regimens, 
the 5-year survival rate has not experienced substantial changes (between 35% to 40%) 
[1,3]. This poor overall prognosis is mostly a result of a combination of factors including the 
absence of distinctive symptoms and specific tumour markers on early stages so that most 
women are diagnosed at an advanced stage. Also, although the standard platinum-paclitaxel-
based combination chemotherapy is initially successful, longer-term treatment is frequently 
compromised by the development of drug-resistant disease and toxicity profile [4,5]. 
Therefore, identification of novel prognostic and predictive markers in HGSOC that may 
help in treatment decision-making and eventually lead to the development of more effective 
therapies is of critical importance.
Over the last years, therapeutic strategies that inhibit DNA repair pathways or take advantage 
of intrinsic alterations in DNA-repair genes in tumors have been extensively considered as 
approaches to improve or predict efficacy of cancer therapies [6]. In particular, many different 
studies throughout the last two decades have evaluated in EOC and other tumour types the 
relation between cisplatin sensitivity and the components of the nucleotide excision repair 
(NER) system, which recognizes the DNA damage induced by platinum-based therapy [7-9]. 
Interestingly, Ceccaldi et al. [11], by using The Cancer Genome Atlas (TCGA) ovarian dataset, 
have recently described a subgroup of HGSOCs with NER alterations associated with a 
phenotype of platinum sensitivity similar to that of BRCA1/2 mutated tumors, with improved 
overall survival (OS) and progression-free survival (PFS) [11].
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We previously showed that loss at 6q24.2-26 region is significantly associated with longer 
survival in HGSOCs independently of known prognostic factors [12]. By integrating copy 
number, RNAseq and survival data of 296 HGSOCs from TCGA, we demonstrated that 
the 6q24.2-26 deletion has an impact on gene expression, and among the genes that 
were significantly downregulated when lost, we defined several candidates, whose lower 
expression showed association with longer survival. One of the candidates proposed to 
explain the association of the 6q24.2-26 loss with survival is the General Transcription factor 
IIH Polypeptide 5 (GTF2H5, also known as TTDA). GTF2H5 encodes for an 8kD protein that 
forms part of the THFII complex, a multi subunit element involved in the local opening of the 
DNA double helix around DNA bulky lesions or interstrand adducts during the NER process 
[13-16]. The fact that GTF2H5 participates in DNA repair, especially in interstrand adducts 
removal [13] makes it a good candidate to perform additional studies in order to confirm its 
prognostic value and to examine its possible role in platinum-based chemotherapy sensitivity.
In the present study, we further explored the association found between survival of EOC 
patients and GTF2H5 both, at the protein expression level by using immunohistochemistry 
(IHC) in a series of 139 HGSOCs, and at the transcription level using publicly available 
independent datasets comprising altogether 855 HGSOCs. We also tested whether by 
including GTF2H5 we reinforced previous findings showing that NER alterations in HGSOCs 
are associated with improved outcome. Finally, in order to evaluate not only its prognostic, 
but also its potential predictive value, we have also performed functional experiments 
to assess whether stable short hairpin RNA (shRNA)-mediated GTF2H5 downregulation 
modulates cisplatin sensitivity in EOC cell lines.
MATERIALS AND METHODS
1. Patients and tumors
A total of 139 formalin fixed paraffin embedded primary HGSOCs were obtained from 
different hospitals throughout Spain after approval of the appropriate Human Research Ethics 
Committees at each participating center. Tumors were distributed in 5 tissue microarrays 
(TMAs) and 117 out of the 139 provided suitable GTF2H5 immunohistological staining 
comprising the final series evaluated in the present study (Supplementary Table 1). Eighty 
tumors were sporadic (with not reported first or second degree relative with breast or ovarian 
cancer) and 37 tumors classified as familial according to the criteria specified somewhere else 
[17]. All cases were blindly reviewed by three pathologists (IMR, JP and DH) and classified 
histopathologically. Histotype verification was assessed by H&E staining and evaluation of 
immunohistochemical markers such as Wilms tumour protein, tumour protein p53, estrogen 
receptor, progesterone receptor, and cyclin-dependent kinase inhibitor 2A. Grading was 
performed according to two-tier MD Anderson Cancer Center system [18,19]. Most cases 
(72.4%) were of high International Federation of Gynecology and Obstetrics (FIGO) stage 
(stages III–IV using the FIGO system). All patients were treated according to a standardized 
protocol with a combination of taxane and platinum agents after debulking surgery. None 
of them had received neoadjuvant treatment. The length of OS was defined from the date of 
primary surgery to the date of patient death. PFS was calculated from the date of primary 
surgery to the date of disease progression, defined as an increase in cancer antigen 125 or 
radiological or surgical evidence of relapse. More detailed clinicopathological information 
is shown in Table 1. All the samples were obtained through The National Cancer Research 
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Centre (CNIO) Biobank, which facilitates access to human samples for research purposes. 
CNIO Biobank was approved by the Spanish Law 14/2007 on Biomedical Research, and Royal 
Decree RD 1716/2011, and is registered in the National Registry of Biobanks with reference 
B.000848. The study was approved by Instituto de Salud Carlos III Research Ethic Committee 
CEI PI 24_2013.
2. Immunohistochemical analysis
Morphology of tumors was reviewed on whole histological sections by gynecological 
specialized pathologists (JP, IMR, and DH) and cores were obtained from selected areas to 
build 5 TMAs as previously specified [20]. TMAs were designed to have two replicate cores for 
each tumour. Four-μm sections from TMAs were prepared with a semiautomatic microtome 
HM3508 (MICROM) and the tissue sections were deparaffinised and rehydrated in water. 
Antigen retrieval was performed in a DAKO PT Link in citrate buffer (pH, 6). Peroxidase 
activity was blocked with Dako Protein block for 10 minutes (containing casein 0.25% in 
phosphate-buffered saline) then incubated for 30 minutes with primary rabbit polyclonal 
anti-human anti-GTF2H5 antibody (1:100, 14539-1-AP, Proteintech, Chicago, IL, USA) for 
30 minutes and detected with Dako Envision Plus kit (Dako, Glostrup, Denmark). Slides 
were counterstained with haematoxylin and coverslipped with DPX mountant for microscopy 
(VWR Int., Radnor, PA, USA). In agreement with the nuclear localization assigned to 
GTF2H5 in UniProtKB/Swiss-Prot according to experiments shown in Giglia-Mari et al. [16] 
immunohistochemical staining pattern of GTF2H5 was predominantly nuclear (Fig. 1). 
Scoring was exclusively based on the percentage of GTF2H5 stained nuclei within tumoural 
areas of each tumour regardless of staining intensity. In tumors with negative staining for 
GTF2H5, positively stained lymphocytes were used as internal positive control.
3. GTF2H5 immunohistochemical staining and survival
The defined tumour categories of high- and low-GTF2H5 immunostaining were evaluated 
for their association with 5-year survival (OS). Five-year follow-up was chosen as survival 
endpoint in order to minimize the effect of non-ovarian cancer related deaths. Estimation of 
survival time distribution was performed using Kaplan-Meier (KM) method and statistical 
differences between curves were assessed with the log rank test. Univariate cox regression 
Table 1.  Clinicopathological features of patients and tumors
Characteristic No. (%)
Total series 117
Familial status
   Sporadic 80 (68.1)
   Familial 37 (31.9)
      BRCA1 16 (43.2)
      BRCA2 7 (19)
      non-BRCA1/2 mutation carrier 13 (35.1)
   Not applicable 1 (2.7)
Age at diagnosis (yr), mean (range) 54 (35–92)
FIGO stage
   I 8 (6.0)
   II 5 (4.3)
   ≥III 84 (72.4)
   Not applicable 20 (17.3)
Overall survival (mo), median (95% CI) 36 (31–43)
Progression-free survival (mo), median (95% CI) 19 (11–26)
FIGO, International Federation of Gynecology and Obstetrics.
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was used to estimate hazard ratios (HRs) and 95% CIs. The Cox regression model was also 
used for multivariate analysis. Time was censored at the date of last follow-up or at 5 years if 
alive, whichever came first. Statistical analyses were performed using SPSS ver. 17.0 (SPSS 
Inc., Chicago, IL, USA). All statistical tests were two-sided and nominal p-values less than 0.05 
were considered statistically significant.
4. Validation at the global gene expression level
The association of GTF2H5 with survival was validated at the gene expression level using 
KM-plotter [21] with the JetSet probset. The KM-plotter is an online tool that allows the 
assessment of the prognostic value of the expression levels of microarray-quantified genes 
in ovarian cancer patients. We used the 2015 version of the database that includes gene 
expression data and survival information of 855 HGSOCs downloaded from Gene Expression 
Omnibus and TCGA (13 different datasets). Data was dichotomized at the automatically 
selected best fitted cut-off into GTF2H5-high and low expressing groups. KM and log-rank 
test were used to characterize the distribution and estimate the outcomes. In addition Cox 
proportional hazard model was used to estimate the HRs and 95% CIs. The association with 
5-year OS and PFS was assessed in the 855 HGSOCs (grade 3) and in a more homogeneous 
group of 388 high FIGO (FIGO III and IV) with optimal debulking surgery HGSOCs.
5. Evaluation of NER alterations in TCGA dataset
Ceccaldi et al. [11] recently described a subset of tumors from TCGA ovarian cancer dataset 
with NER alterations (8% of the series) that were associated with improved OS and PFS [11]. 
Since the authors did not evaluate GTF2H5 we aimed to determine whether by reproducing 
the previously published analysis but with inclusion of GTF2H5 such associations were 
maintained or improved. As previously described [11] we accessed data for 316 patients with 
A B C
D E F
200 µm 200 µm
200 µm 200 µm 200 µm
200 µm
Fig. 1.  Immunohistochemical analysis of GTF2H5 expression in high-grade serous ovarian carcinomas. 
Representative immunostaining of tumors belonging to the low- (A-C) and high- (D-F) GTF2H5 staining 
categories. Median stained nuclei in the series (5%) was used as threshold to define low (≤5%) and high (>5%) 
categories. Images correspond to tumour cores included in tissue microarrays.
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HGSOC in TCGA dataset for which promoter methylation, messenger RNA expression, DNA 
copy number and DNA sequencing information of exons was available [11,22] and evaluated 
NER genes (XPA, XPC, DDB1, ERCC4, ERCC5, ERCC2, ERCC3, ERCC1, ERCC6, PCNA, ERCC8, LIG1, 
RAD23B, MNAT1, MMS19, RFC1, XAB2) for nonsynonymous or splice site mutations, promoter 
hypermethylation and homologous deletions concurrent with low mRNA expression levels. 
Since GTF2H5 does not shows mutations or bialellic deletions in TCGA dataset we evaluated 
those tumors that exhibit GTF2H5 low expression levels using stringent criteria (mRNA 
expression Z-score of less than –3). We then assessed associations with OS and PFS by using 
the KM method and log-rank test. Tumors that harboured BRCA mutation were not included 
in the survival analysis. As in Ceccaldi et al. [11], four samples with both, BRCA and NER 
mutations were also excluded.
6. Cell lines and cultures
Human ovarian cancer SKOV3 cells [23] were purchased from the American Type Culture 
Collection and cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and 0.5% fungizone. COV504 cell line [24] was obtained from 
European Collection of Cell Culture and grown in Dulbecco's Modified Eagle's Medium with 
10% FBS, 1% penicillin/streptomycin, and 0.5% fungizone. Cells were cultured at 37°C in a 
humidified 5% CO2 atmosphere.
7. shRNA mediated GTF2H5 silencing in ovarian cancer cell lines
shRNAs for human GTF2H5 (NM_207118) were obtained from Sigma-Aldrich (MISSION 
shRNA Bacterial Glycerol Stock, St. Louis, Mo, USA). Three different shRNA constructs were 
transduced and the one providing the best knockdown efficiency and non-cytotoxic effects 
was selected (SH3, TRCN0000062802) to stably-silence GTF2H5 expression in the SKOV3 
and COV504 ovarian cell lines. A MISSION non-target shRNA vector (Scramble SHC002) 
was used as negative control. Briefly, lentiviral vectors were cotransfected with lentiviral 
packaging plasmids into 293FT cells (Invitrogen, Carlsbad, CA, USA) in the presence of 
Fugene 6 (Promega, Madison, WI, USA). The virus-containing supernatants were collected 
after 36 hours of transfection and filtered. Cells were infected and the stably transduced cells 
were selected by adding medium containing 1 mg/mL of puromycin. Silencing efficiency was 
tested by real-time quantitative polymerase chain reaction (qPCR) due to lack of available 
GTF2H5 antibody for Western blot analysis.
8. Real-time quantitative polymerase chain reaction
Total RNA was extracted from three independent plates for each cell line (RNAeasy Kit, 
Quiagen, Valencia, CA, USA) and converted to cDNA by using 500 ng as template (High 
Capacity cDNA RT kit, Applied Biosystems, Foster City, CA, USA). qPCR assays were designed 
for target gene (GTF2H5) and endogenous control (β-actin) using the Roche Universal Probe 
Library Assay Design Centre web site (Roche Applied Science, Indianapolis, IN, USA). 
Reactions were performed in triplicate using the ABI Prism 7900HT Sequence Detection 
System according to the manufacturer’s protocol (Applied Biosystems). Relative expression 
was determined using the qBase software that allows for PCR efficiency correction and 
implements normalization by endogenous gene.
9. WST-1 cytotoxicity assay
To evaluate the inhibition of cell viability by cisplatin treatment, 5×103 cells/well were pre-
seeded 24 hours before treatment into a 96-well plate. Cells were treated with increased 
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concentrations of cisplatin (0 to 80 μM) for 72 hours, and the WST-1 reagent was added to 
each well according to the manufacturer’s instructions (Roche Applied Science, Indianapolis, 
IN, USA). After 4 hours, cell viability was measured at an absorbance of 450 nm using a plate 
reader (Wallac 1420 VICTOR, PerkinElmer, Waltham, MA, USA).
RESULTS
1. IHC analysis of GTF2H5 expression
In order to further validate our prior finding of GTF2H5 association with survival [12], we 
analyzed GTF2H5 expression at the protein level by using immunohistochemistry in 139 
HGSOCs assembled on 5 TMAs. A total of 117 tumour cores were interpretable for GTF2H5 
staining, of which 107 (91.4%) had associated survival information. Uninterpretable 
staining was due to lack of enough tumour cells in the core or to complete core loss. Scoring 
of GTF2H5 was based on the percentage of positive tumoural nuclei regardless intensity. 
Values ranged between complete absence of staining and 100% stained cells with a median 
staining value of 5% in the series. High- and low-GTF2H5 staining categories of tumors 
were established according to the median staining value (high, >5%; low ≤5%). Fig. 1 shows 
representative examples of HGSOCs belonging to both categories. We evaluated whether 
GTF2H5 staining was associated with residual tumor size and other known prognosis 
markers such as FIGO stage, age of diagnosis, and immunohistochemical expression of the 
progesterone receptor [25] and we did not find statistically significant differences (p>0.05; 
Pearson chi-square test).
2. Low GTF2H5 IHC staining is associated with better survival in HGSOC
Association of GTF2H5 immunohistochemical expression with survival was assessed by KM 
analysis and log-rank test. We found significant differences in the 5-year survival between 
patients belonging to the GTF2H5-Low expression category (≤5% staining) and patients in 
the GTF2H5-High expression group (>5% staining; HR, 0.52; 95% CI, 0.29 to 0.93; p=0.024) 
with survival rates of 59% and 33.8%, respectively (Fig. 2A). Since ovarian cancer patients 
with BRCA1 or BRCA2 germline mutations have been shown to present better survival [26] and 
our series included familial ovarian cancer cases, we considered this variable as a possible 
confounder. We adjusted for this factor in the group of patients with known BRCA status 
(mutated or non-mutated) and the association remained statistically significant (HR, 0.19; 
95% CI, 0.04 to 0.89; p=0.035).
3. Decreased GTF2H5 expression levels are associated with better prognosis 
in a multi-institution HGSOC validation dataset
After finding significant differences in survival outcomes in our TMA set of samples 
stratified according to GTF2H5 IHC staining, we decided to extend the analysis to a larger 
and independent cohort of patients. To this end, we used the KM plotter, a free online tool 
that provides microarray gene expression data of 22, 277 genes in 855 HGSOCs from 13 
different datasets [21]. In agreement with our IHC data we found that low expression of the 
GTF2H5 gene was associated with improved 5-year OS in 855 HGSOCs (HR, 0.80; 95% CI, 
0.65 to 0.97; p=0.023) (Fig. 2B). To account for the effect of confounding factors other than 
histology and grade, we analyzed a more homogeneous group of 388 HGSOC of high FIGO 
stage (stage III and IV) and optimal debulking status, and the association was confirmed 
not only for improved 5-year OS (HR, 0.55; 95% CI, 0.38 to 0.78; p=0.0007) (Fig. 2C), but 
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Fig. 2.  GTF2H5 expression is associated with longer survival in high-grade serous ovarian carcinomas (HGSOCs). (A) Kaplan-Meier survival curve showing a 
significant association between GTF2H5 immunohistochemical staining and 5-year survival. Patients with tumors belonging to the low staining group (≤5%) 
presented improved 5-year survival compared to the high-GTF2H5 staining group (>5%; p=0.024). (B-D) Kaplan-Meier curves from the Kaplan-Meier Plotter 
online tool. Lower transcriptional expression of GTF2H5 predicted enhanced 5-year survival in HGSOCs (p=0.023) (B) and in a homogenous group of high 
International Federation of Gynecology and Obstetrics (FIGO) stage optimally debulked HGSOCs (p=0.0007) (C). In high-FIGO stage optimally debulked HGSOCs 
there was also an association with improved progression-free survival (p=0.026) (D). The number of patients at risk at specific time points is shown below each 
diagram. The p<0.05 were considered to be statistically significant.
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also for increased PFS (HR, 0.72; 95% CI, 0.54 to 0.96; p=0.026) (Fig. 2D). Altogether, these 
results suggest a significant prognostic relevance and a potential predictive value of GTF2H5 
expression in HGSOCs.
4. GTF2H5 low expression reinforces the recently described association of 
NER alterations with improved PFS in HGSOCs
Upon the recent finding that HGSOCs from TCGA series with NER alterations are associated 
with improved OS and PFS [11], we decided to test whether by evaluating low GTF2H5-
expressing tumors we maintained or improved such associations. With the criteria used in the 
previous published analysis, we found 24 of 316 tumors (8%) with NER alterations and also 
retrieved 9 additional tumors (3%) with low GTF2H5 expression using a stringent threshold 
(mRNA expression Z-score of less than –3) (Supplementary Fig. 1A). All NER alterations 
among themselves, but also in relation to GTF2H5 low expression, were mutually exclusive. 
Patients with tumors with NER alterations including those consisting of low GTF2H5 
expression maintained a statistically significant higher median OS compared with patients 
with tumors without NER alterations and BRCA1/2 mutation (log-rank p=0.027). More 
importantly, in this comparison, the previously found trend toward statistically significantly 
higher median PFS in patients with NER alterations, reached significance by including low 
GTF2H5-expressing tumors (log-rank p=0.021) (Supplementary Fig. 1B).
5. GTF2H5 downregulation increases platinum sensitivity in HGSOC cell lines
In order to further evaluate the potential predictive value of GTF2H5 expression levels, we 
aimed to determine the relationship between GTF2H5 deficiency and cisplatin sensitivity. 
For this purpose, by using specific shRNAs, we knocked down GTF2H5 in the ovarian cancer 
cell line SKOV3 and assessed cisplatin sensitivity. Knockdown efficiency of three different 
GTF2H5 shRNAs was tested by reverse transcription-qPCR (data not shown) and the 
construct that provided the highest efficiency was selected to carry out cytotoxicity assays 
Fig. 3.  GTF2H5 downregulation modulates cisplatin sensitization of ovarian cancer cells. (A) GTF2H5 expression in SKOV3 and COV504 ovarian cancer cell lines 
transduced with control (scramble) or GTF2H5-specific short hairpin RNA (shRNA). Data represent actin-normalized and relative to control mRNA expression 
levels of GTF2H5, as determined by real-time quantitative polymerase chain reaction. Data correspond to the mean of three independent experiments. (B) 
SKOV3 and COV504 ovarian cells transduced with control or GTF2H5-specific shRNA were treated with different concentrations of cisplatin for 72 hours and 
a standard WST-1 cytotoxicity assay was conducted to determine cell survival. A significant reduction in the half maximal inhibitory concentration (IC50) upon 
cisplatin treatment was observed in the GTF2H5-silenced SKOV3 cells compared with control cells (p<0.05). Consistent results were observed in GTF2H5-
silenced COV504 ovarian cells. Values represent the SE of three independent experiments.
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(Fig. 3A). We observed a significant reduction in the half maximal inhibitory concentration 
(IC50) upon cisplatin treatment in the GTF2H5-silenced SKOV3 cells compared with control 
cells (transduced with scramble vector, p<0.05) (Fig. 3B). In order to further assess the 
generality of this result we also tested GTF2H5 silencing effect in COV504 cells (Fig. 3A). In 
this additional ovarian cancer cell model, a similar increase in cisplatin sensitivity was 
observed (Fig. 3B).
DISCUSSION
Less than 30% of ovarian cancer patients with advanced stage can be cured with the current 
standard treatment [27], which makes the definition of novel prognostic and predictive 
factors a priority in the field. Such markers may improve patients’ outcome by helping to 
select more appropriate therapeutic regimens and by providing insight into tumour biology 
that may eventually lead to the development of more effective targeted therapies.
Previous work carried out by our group demonstrated that a genomic loss of 6q24.2-26 
region predicts better prognosis in HGSOC patients independently of known factors [12]. 
Identification of the deletion presents itself potential clinical value, as it could be used to 
guide the selection of patients towards more conservative therapeutic strategies in order to 
reduce side-effects and improve quality of life. However, further evaluation of the role played 
by the genes located in the lost region is essential to understand the possible mechanisms 
that drive the association and to reveal potential predictive significance. The NER-related 
gene GTF2H5 was among the candidates proposed to explain the association. GTF2H5 is 
a subunit of the transcription factor II human (TFIIH) complex, which is involved in the 
opening of the DNA double helix during the NER process. Nowadays the specific role of 
GTF2H5 in the complex remains controversial. Different studies suggest that GTF2H5 
function could be focused on stabilization and protection of TFIIH from degradation [16] 
with a function presumed to make NER more efficient [28]. Other proposed its essential role 
in NER pathway and in embryonic development [29].
In the present study we found that low GTF2H5 protein expression defined by 
immunohistochemical staining is associated with improved 5-years OS in HGSOC patients. In 
addition, the analysis of 13 previously published transcriptomic datasets available in the KM-
plot web tool [21] showed that HGSOCs with low-GTF2H5 expression levels present better 
5-year OS than those with high-GTF2H5 expression levels. Altogether, these observations 
would confirm the prognostic value of GTF2H5 and upon validation in prospective studies 
this marker could assist in the selection of patients whose favorable outcome would support 
the use of new treatment regimens that aim to improve tolerability without jeopardizing 
efficacy. The possibility to evaluate GTF2H5 levels by using IHC on paraffin blocks is 
particularly interesting because this is the standard material routinely used for clinical 
diagnostic.
Besides the association with 5-year OS, our results also revealed an association of low-GTF2H5 
expression with higher median PFS in a homogeneous group of optimally debulked high-
FIGO stage HGSOC patients. PFS is a meaningful outcome measure of platinum response 
and this result supports the hypothesis that GTF2H5 might also have a predictive value for 
platinum-based therapy. Consistently, by including low GTF2H5-expressing tumors, the 
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recent finding that patients with tumors with NER alterations present improved PFS [11] was 
reinforced. Also, shRNA-mediated GTF2H5-knock-down experiments showed a modest but 
significant cisplatin sensitization in ovarian cancer cell lines. Altogether, these findings are in 
agreement with the role of GTF2H5 in facilitating a more efficient NER [28] and in line with 
previous observations that cisplatin is generally more active in NER-compromised ovarian 
tumors [9,30].
Although we have been able to verify the individual prognostic value of GTF2H5 we should 
not overlook other candidate genes in the 6q24.2-26 region, such as ARID1B that forms part 
of the switch/sucrose non-fermentable (SWI/SNF) complexes that are involved in double 
strand break repair [31,32] or the SNF2 histone linker PHD RING helicase SHPRH that plays 
a crucial role in an error-free repair of stalled replication forks caused by DNA damage [33]. 
It is plausible that the modest cisplatin sensitization effect observed by GTF2H5 silencing 
is additive or synergistic to the contribution of other DNA-repair related genes lost in the 
6q24.2-26 deletion. Interestingly, a recent high-throughput data-based study defined 6q15-27 
among eight DNA copy number losses that significantly affect candidate pathways associated 
with chemoresponse in EOC [34].
In conclusion, we have shown that low protein and expression levels of the NER-related gene 
GTF2H5 are associated with enhanced prognosis in HGSOC. In addition we provide evidence 
that GTF2H5 downregulation may also contribute to cisplatin sensitization. Our results 
warrant prospective validation in order to be translated into clinical practice and support 
further evaluation of the specific and combined effect of other candidates at 6q24.2-26.
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